Advertisement

Topics

Search Results for "Pharmac Cost Of Sativex In New Zealand"

16:43 EDT 30th August 2016 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...

CombiCult

CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

New Zealand public help improve PHARMAC decision making

After listening to what New Zealanders had to say, the country’s Pharmaceutical Management Agency PHARMAC…

PHARMAC proposes listing of Harvoni and Viekira Pak

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on two proposals to list…

NZ’s PHARMAC to list Praxbind and achieves price cut on Pradaxa

New Zealand’s Pharmaceutical Management Agency PHARMAC today announced the approval of an agreement…

NZ’s PHARMAC consults on proposed listing of Praxbind and Pradaxa

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal involving…

NZ’s PHARMAC considers listing of Amgen’s Sensipar

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list cinacalcet…

NZ’s PHARMAC to list Janssen’s Sirturo and Sylvant for rare disorders

New Zealand’s Pharmaceutical Management Agency PHARMAC announced this morning the approval of an agreement…

NZ’s PHARMAC to fund Sensipar; consult on Sirturo, Sylvant

New Zealand’s Pharmaceutical Management Agency PHARMAC announced today its decision to list cinacalcet…

NZ’s PHARMAC proposals on funding Opdivo, Keytruda, Noxafil and Isentress

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced a decision to fund nivolumab (trade…

Matching PubMed Articles

Is cost-related non-collection of prescriptions associated with a reduction in health? Findings from a large-scale longitudinal study of New Zealand adults.

To investigate whether cost-related non-collection of prescription medication is associated with a decline in health.

Pacemaker Use in New Zealand - Data From the New Zealand Implanted Cardiac Device Registry (ANZACS-QI 15).

The New Zealand Cardiac Implanted Device Registry (Device) has recently been developed under the auspices of the New Zealand Branch of the Cardiac Society of Australia and New Zealand. This study desc...

Burden of disease from second-hand smoke exposure in New Zealand.

To estimate the number of deaths and disability-adjusted life years (DALYs) attributable to secondhand smoke in New Zealand.

Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series.

Cannabis is the most commonly used illicit drug; a substantial minority of users develop dependence. The current lack of pharmacological treatments for cannabis dependence warrants the use of novel ap...

The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ(9)-tetrahydrocannabinol acting through CB1 receptors.

Sativex®, an equimolecular combination of Δ(9)-tetrahydrocannabinol-botanical drug substance (Δ(9)-THC-BDS) and cannabidiol-botanical drug substance (CBD-BDS), is a licensed medicine that may be pr...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement